All Posts

We've been working with BPIQ AI to provide more information about upcoming catalysts for investors to consider in their diligence of smid-cap biopharma companies. For October and November 2026, BPIQ AI estimated the probability (FN1) that each of 20 Phase 2 and Phase 3 readouts will read out as a clean positive, a clean negative, or with mixed data, along with the potential stock move for each outcome. In this free post, we reveal one of them: the readout BPIQ AI likes least.

We've been working with BPIQ AI to provide more information about upcoming catalysts for investors to consider in their diligence of smid-cap biopharma companies. The table below shows BPIQ AI's predicted probabilities (FN1) that each of 20 October and November 2026 Phase 2 and Phase 3 readouts, across 16 companies, will read out as a clean positive, a clean negative, or with mixed data, along with its predicted stock move for each outcome. Keep in mind that predicting cataly

ADCs offer a compelling prospect: deliver a potent cancer drug to tumors with greater precision, then turn that approach into meaningful patient benefit. Enhertu has shown what that can look like. It improved survival in HER2-positive metastatic breast cancer and has since expanded into earlier treatment settings. It was also the only ADC in the top 10 oncology drugs by sales for 2025 and H1 2026. For bio/pharma investors, the question is which programs have the evidence to f

Our September Pro pick is VRDN. With Lumvoa approved and positive follow-on Phase 3 results, attention turns to its TED launch and planned Q1 2027 filing. Read the full VRDN report.

3 September hedge fund picks face different tests: VRDN’s TED launch, MAZE’s updated kidney-disease data, and ANNX’s pivotal GA assessment. Compare the catalysts and risks behind each.

We reveal VRDN as one of September’s three hedge fund stock picks. Its TED trials are behind it, while launch execution and a follow-on filing lie ahead.

Explore BPIQ-AI forecasts for September 2026 Phase 2 and Phase 3 readouts, including Clean+, Mixed, and Clean− probabilities, expected stock move ranges, and insights from live options data.

Explore BPIQ-AI forecasts for September 2026 Phase 2 and Phase 3 readouts, including Clean+, Mixed, and Clean− probabilities, expected stock move ranges, and insights from live options data.

Explore BPIQ-AI forecasts for September 2026 Phase 2 and Phase 3 readouts, including Clean+, Mixed, and Clean− probabilities, expected stock move ranges, and insights from live options data.

Summary Hedge fund holdings can help you discover new investment ideas We identified & follow the top biopharma-focused hedge funds Q2 hedge fund holdings reports were released on ~08/14/26 This report focuses on top holdings of top biopharma hedge funds as of 06/30/26 Top Biopharma Hedge Funds At BPIQ we identified the top smid-cap biopharma-focused hedge funds ^1. We updated our database of holding and other info re: these funds with their recently-released data for holdings